Evaluating the Antibacterial Efficacy of Margatoxin Against Ciprofloxacin-Resistant Pseudomonas aeruginosa Clinical Isolates
محورهای موضوعی : Biotechnological Journal of Environmental MicroorganismsSanaz Borji 1 , Mahdi Shariarinour 2 , Shahab Shariati 3 , Najmeh Ranji 4 , Mohammad Nikpassand 5
1 - Department of Biology, Ra. C., Islamic Azad University, Rasht, Iran
2 - Department of Biology, Ra. C., Islamic Azad University, Rasht, Iran
3 - Department of Chemistry, Ra. C., Islamic Azad University, Rasht, Iran
4 - Department of Biology, Ra. C., Islamic Azad University, Rasht, Iran
5 - Department of Chemistry, Ra. C., Islamic Azad University, Rasht, Iran
کلید واژه: Margatoxin, Fe3O4@SiPr, Pseudomonas aeruginosa, silibinin ,
چکیده مقاله :
Pseudomonas aeruginosa is a gram-negative opportunistic pathogen and a major multidrug-resistant organism due to its high adaptability and ability to withstand various classes of antibiotics. Ciprofloxacin resistance strains, in particular, have become a significant clinical concern. . This study evaluated the antibacterial activity of margatoxin (MgTX), a scorpion-derived peptide, against ciprofloxacin-resistant P. aeruginosa clinical isolates. Twenty clinical isolates of P. aeruginosa was obtained from hospital bacteriology laboratories. Antimicrobial susceptibility to piperacillin (100 μg), imipenem (10 μg), ceftazidime (30 μg), amikacin (30 μg), and ciprofloxacin (5 μg) was determined using the Kirby–Bauer disk diffusion method. Biofilm formation was assessed using the microtiter plate assay. The synergistic interaction between MgTX with ciprofloxacin was evaluated using the checkerboard method. All isolates exhibited ≥90% resistance to the tested antibiotics. Ciprofloxacin resistance levels ranged from 128 to 1024 μg/mL. against ciprofloxacin. All isolates were capable of forming biofilms, displaying weak to strong biofilm phenotypes. Checkerboard analysis demonstrated a synergistic interaction between MgTX and ciprofloxacin. resulting in dose-dependent inhibition growth. The findings indicate that margatoxin may serve as a potential alternative or adjunct therapeutic agent for managing ciprofloxacin-resistant Pseudomonas aeruginosa infections. Its antibacterial activity likely involves interaction with specific bacterial targets and induction of cell death, possibly through membrane disruption. However, further research—including toxicity assessment, mechanism-of-action studies, and in vivo evaluations—is required before determining its suitability for clinical application.
Pseudomonas aeruginosa is a gram-negative opportunistic pathogen and a major multidrug-resistant organism due to its high adaptability and ability to withstand various classes of antibiotics. Ciprofloxacin resistance strains, in particular, have become a significant clinical concern. . This study evaluated the antibacterial activity of margatoxin (MgTX), a scorpion-derived peptide, against ciprofloxacin-resistant P. aeruginosa clinical isolates. Twenty clinical isolates of P. aeruginosa was obtained from hospital bacteriology laboratories. Antimicrobial susceptibility to piperacillin (100 μg), imipenem (10 μg), ceftazidime (30 μg), amikacin (30 μg), and ciprofloxacin (5 μg) was determined using the Kirby–Bauer disk diffusion method. Biofilm formation was assessed using the microtiter plate assay. The synergistic interaction between MgTX with ciprofloxacin was evaluated using the checkerboard method. All isolates exhibited ≥90% resistance to the tested antibiotics. Ciprofloxacin resistance levels ranged from 128 to 1024 μg/mL. against ciprofloxacin. All isolates were capable of forming biofilms, displaying weak to strong biofilm phenotypes. Checkerboard analysis demonstrated a synergistic interaction between MgTX and ciprofloxacin. resulting in dose-dependent inhibition growth. The findings indicate that margatoxin may serve as a potential alternative or adjunct therapeutic agent for managing ciprofloxacin-resistant Pseudomonas aeruginosa infections. Its antibacterial activity likely involves interaction with specific bacterial targets and induction of cell death, possibly through membrane disruption. However, further research—including toxicity assessment, mechanism-of-action studies, and in vivo evaluations—is required before determining its suitability for clinical application.
1. Farzin, A., M.M. Rahman, and F.A. Mollika, Pseudomonas aeruginosa: the alarming pathogen of hospital acquired infection. 2023.
2. Sanya, D.R.A., et al., Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections. BMC microbiology, 2023. 23(1): p. 86.
3. De Soir, S., et al., Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. Microbiology Spectrum, 2024. 12(1): p. e03219-23.
4. Jhalora, V. and R. Bist, A Comprehensive Review of Molecular Mechanisms Leading to the Emergence of Multidrug Resistance in Bacteria. Indian Journal of Microbiology, 2024: p. 1-22.
5. Karnwal, A., et al., Perspectives on usage of functional nanomaterials in antimicrobial therapy for antibiotic-resistant bacterial infections. ACS omega, 2023. 8(15): p. 13492-13508.
6. Alabdali, Y.A.J., et al., Molecular Analysis of Pseudomonas aeruginosa Isolates with Mutant gyrA Gene and Development of a New Ciprofloxacin Derivative for Antimicrobial Therapy. Molecular Biotechnology, 2024: p. 1-12.
7. Samat, R., et al., Venom: A Promising Avenue for Antimicrobial Therapeutics. ACS Infectious Diseases, 2024. 10(9): p. 3098-3125.
8. Xia, Z., et al., Antimicrobial Potential of Scorpion-Venom-Derived Peptides. Molecules, 2024. 29(21): p. 5080.
9. Xia, Z., et al., Scorpion venom peptides: Molecular diversity, structural characteristics, and therapeutic use from channelopathies to viral infections and cancers. Pharmacological Research, 2023. 197: p. 106978.
10. Serafin, P., et al., Evaluation of antimicrobial activities against various E. coli strains of a novel hybrid peptide—LENART01. Molecules, 2023. 28(13): p. 4955.
11. Silva, O.N., et al., Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties. Proceedings of the National Academy of Sciences, 2020. 117(43): p. 26936-26945.
12. Naseem, M.U., Studying interactions between peptide toxins and voltage-gated K+ channels at the molecular level.
13. Rojas-Palomino, J., et al., Electrophysiological evaluation of the effect of peptide toxins on voltage-gated ion channels: a scoping review on theoretical and methodological aspects with focus on the Central and South American experience. Journal of Venomous Animals and Toxins including Tropical Diseases, 2024. 30: p. e20230048.
14. Gigante, V., et al., Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps. Antimicrobial Agents and Chemotherapy, 2024. 68(8): p. e00535-24.
15. Beltrán-Vidal, J., et al., Colombian scorpion Centruroides margaritatus: Purification and characterization of a gamma potassium toxin with full-block activity on the hERG1 channel. Toxins, 2021. 13(6): p. 407.
16. Ortiz, E., et al., Scorpion venom components as potential candidates for drug development. Toxicon, 2015. 93: p. 125-135.
17. Lu, C.-L., et al., Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrobial agents and chemotherapy, 2011. 55(9): p. 4295-4301.
18. Gupta, A., et al., Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection. Nano Futures, 2017. 1(1): p. 015004.
19. Guglielmi, P., V. Pontecorvi, and G. Rotondi, Natural compounds and extracts as novel antimicrobial agents. Expert Opinion on Therapeutic Patents, 2020. 30(12): p. 949-962.
20. Laxminarayan, R., et al., Antibiotic resistance—the need for global solutions. The Lancet infectious diseases, 2013. 13(12): p. 1057-1098.
21. Rincón-Cortés, C.A., et al., Antimicrobial activity developed by scorpion venoms and its peptide component. Toxins, 2022. 14(11): p. 740.
22. Mendes, L.C., et al., Scorpion peptides and ion channels: an insightful review of mechanisms and drug development. Toxins, 2023. 15(4): p. 238.
23. Mohanty, H., S. Pachpute, and R.P. Yadav, Mechanism of drug resistance in bacteria: efflux pump modulation for designing of new antibiotic enhancers. Folia Microbiologica, 2021. 66(5): p. 727-739.
24. Pashmforoosh, N. and M. Baradaran, Peptides with Diverse Functions from Scorpion Venom: A Great Opportunity for the Treatment of a Wide Variety of Diseases. Iranian biomedical journal, 2023. 27(2-3): p. 84.
25. Akef, H.M., Anticancer and antimicrobial activities of scorpion venoms and their peptides. Toxin reviews, 2019. 38(1): p. 41-53.
26. Primon-Barros, M. and A. José Macedo, Animal venom peptides: potential for new antimicrobial agents. Current topics in medicinal chemistry, 2017. 17(10): p. 1119-1156.
